[go: up one dir, main page]

Lyubartseva et al., 2010 - Google Patents

Alterations of zinc transporter proteins ZnT‐1, ZnT‐4 and ZnT‐6 in preclinical Alzheimer's disease brain

Lyubartseva et al., 2010

View PDF
Document ID
6486426715929554008
Author
Lyubartseva G
Smith J
Markesbery W
Lovell M
Publication year
Publication venue
Brain pathology

External Links

Snippet

Our previous studies demonstrate alterations of zinc (Zn) transporter proteins ZnT‐1, ZnT‐4 and ZnT‐6 in vulnerable brain regions of subjects with mild cognitive impairment (MCI), and early and late stage Alzheimer's disease (AD), suggesting disruptions of Zn homeostasis …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Similar Documents

Publication Publication Date Title
Lyubartseva et al. Alterations of zinc transporter proteins ZnT‐1, ZnT‐4 and ZnT‐6 in preclinical Alzheimer's disease brain
Iulita et al. Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study
Manczak et al. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease
Branca et al. Dyrk1 inhibition improves Alzheimer's disease‐like pathology
Sau et al. Mutation of SOD1 in ALS: a gain of a loss of function
Cuadrado-Tejedor et al. Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-β
Manczak et al. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease
Smith et al. Altered expression of zinc transporters-4 and-6 in mild cognitive impairment, early and late Alzheimer’s disease brain
Larson et al. The complex PrPc-Fyn couples human oligomeric Aβ with pathological Tau changes in Alzheimer's disease
De Kimpe et al. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome
Florenzano et al. Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer’s disease and other tauopathies
Henkins et al. Extensive p‐tau pathology and SDS‐stable p‐tau oligomers in Alzheimer's cortical synapses
Grabrucker et al. Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold
Youmans et al. Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations
Nunomura et al. Intraneuronal amyloid β accumulation and oxidative damage to nucleic acids in Alzheimer disease
Oh et al. Clusterin contributes to early stage of Alzheimer's disease pathogenesis
Zhang et al. Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain
Ma et al. Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease
Chen et al. Wolframin is a novel regulator of tau pathology and neurodegeneration
Sokolow et al. High levels of synaptosomal Na+–Ca2+ exchangers (NCX1, NCX2, NCX3) co-localized with amyloid-beta in human cerebral cortex affected by Alzheimer's disease
Lyubartseva et al. A potential role for zinc alterations in the pathogenesis of Alzheimer's disease
US20110256565A1 (en) Methods for diagnosis and treatment of neurodegenerative diseases or disorders
Hass et al. Disease-, region-and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
Roh et al. Mitochondrial dysfunction and calcium deregulation by the RanBP9-cofilin pathway
US20160244805A1 (en) Methods for screening to identify therapeutic agents for alzheimer's disease and use thereof